<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01816789</url>
  </required_header>
  <id_info>
    <org_study_id>ANDROS-01-13</org_study_id>
    <nct_id>NCT01816789</nct_id>
  </id_info>
  <brief_title>Age Versus Ovarian Reserve Markers Based Therapy in IVF (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycles</brief_title>
  <official_title>Age Versus Ovarian Reserve Markers Based Therapy in IN Vitro Fertilization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andros Day Surgery Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Andros Day Surgery Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized controlled trial has been designed for carrying out a comparison of new AMH
      (Anti-Müllerian Hormone)-based individualized treatment (using a nomogram) with the wide
      accepted age-based strategy. The main objective of the trial is to assess whether an
      individualized FSH starting dose can increase the rate of women with an adequate ovarian
      response in terms of retrieved oocytes (optimal number of retrieved oocytes: 8-14).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before clinicians can adopt any model into routine clinical practice, the accuracy of the
      model should be independently evaluated in a population different from the one on which the
      model was elaborated. External validation of the model is therefore crucial to assess the
      generalizability to other populations.

      In the present RCT the new AMH-based individualized treatment will be compared to the wide
      accepted age-based strategy.

      Primary endpoint:

      The percentage of women with an appropriate number (n=8-14) of retrieved oocytes in IVF/ICSI
      cycle.

      Secondary endpoints:

        1. Serum E2 levels on r-hCG day

        2. Serum P levels on r-hCG day

        3. Number of growing follicles (≥11mm) on r-hCG day

        4. Number of large (≥ 17 mm) ovarian follicles on r-hCG day

        5. Total r-FSH dose employed

        6. Treatment duration

        7. Rate of women with dose adjustment

        8. Number of cancelled cycles because of poor and hyper-response

        9. Fertilization rate

       10. Embryos obtained

       11. Implantation rates

       12. Biochemical pregnancy rates

       13. Clinical pregnancy rates

       14. OHSS rates
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Optimal response: 63% nomogram, 42% controls, overcoming the stopping rule for interim analysis
  </why_stopped>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of women with an appropriate number (N=8-14) of retrieved oocytes in IVF/ICSI cycles</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">194</enrollment>
  <condition>In Vitro Fertilization</condition>
  <condition>Ovarian Stimulation</condition>
  <arm_group>
    <arm_group_label>Group A: &quot;age&quot;</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A: long standard protocol (buserelin 0.1 ml s.c. twice per day from the 21st day of the cycle, until the end of gonadotropin administration) + 150 IU of rFSH (starting dose) if female age was ≤35 years or 225 IU of rFSH if female age was ≥ 36 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: &quot;nomogram&quot;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B: long standard protocol (buserelin 0.1 ml s.c. twice per day from the 21st day of the cycle until the end of gonadotropin administration) + individualized starting dose of rFSH on the basis of the nomogram.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rFSH</intervention_name>
    <arm_group_label>Group A: &quot;age&quot;</arm_group_label>
    <arm_group_label>Group B: &quot;nomogram&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>buserelin</intervention_name>
    <arm_group_label>Group A: &quot;age&quot;</arm_group_label>
    <arm_group_label>Group B: &quot;nomogram&quot;</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  first or second IVF/ICSI attempt (the second one after 6 months from the first
             one);regular menstrual cycles (25-33 days);female age ≤ 40; day 3 FSH ≤
             15IU/L;treatment with a long GnRH agonist protocol (buserelin)+rFSH;BMI: &gt;18 and ≤ 25
             kg/m2;presence of both ovaries.

        Exclusion Criteria:

          -  irregular cycles, anovulatory infertility, endometriosis III-IV stage AFS, use of
             adjunctive therapies for stimulation, evidence of PCO status, previous ovarian
             surgery, presence of ovarian cysts, history of PID, use of hormonal contraception in
             the previous 3 months, any known metabolic or endocrinological disease, AMH levels &lt; 1
             and &gt; 4.0 ng/ml
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ANDROS Day Surgery Clinic</name>
      <address>
        <city>Palermo</city>
        <state>Sicily</state>
        <zip>90144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2013</study_first_submitted>
  <study_first_submitted_qc>March 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2013</study_first_posted>
  <last_update_submitted>December 22, 2016</last_update_submitted>
  <last_update_submitted_qc>December 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Starting dose</keyword>
  <keyword>rFSH</keyword>
  <keyword>controlled</keyword>
  <keyword>ovarian</keyword>
  <keyword>stimulation</keyword>
  <keyword>IVF/ICSI</keyword>
  <keyword>cycles</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buserelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

